Lupin informs about press release

24 Dec 2018 Evaluate

Lupin has informed about submission of a Press Release as regards AbbVie Inc. having licensed the company’s MALTI (Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein I) inhibitor program through which AbbVie gains exclusive global rights to develop and commercialize the company’s MALTI inhibitors. This disclosure is under pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×